Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 35

1.

Use of Non-Linear Ultrasonic Techniques to Detect Cracks Due to Steel Corrosion in Reinforced Concrete Structures.

Climent MÁ, Miró M, Carbajo J, Poveda P, de Vera G, Ramis J.

Materials (Basel). 2019 Mar 9;12(5). pii: E813. doi: 10.3390/ma12050813.

2.

Best treatment options for advanced renal cell carcinoma (RCC) patients: a Delphi consensus study.

Pérez-Gracia JL, Castellano D, Climent MÁ, Mellado B, Suárez C.

Med Oncol. 2019 Feb 19;36(3):29. doi: 10.1007/s12032-019-1251-7.

PMID:
30783817
3.

[Multidisciplinary teams in the treatment of prostate cancer.]

Climent MÁ, Rubio-Briones J.

Arch Esp Urol. 2018 Mar;71(3):315-322. Spanish.

PMID:
29633953
4.

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.

Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Hitre E, Graas MP, Simoncini E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, Marth C, Müller B, O'Reilly S, Di Lauro V, Gombos A, Ruhstaller T, Burstein H, Ribi K, Bernhard J, Viale G, Maibach R, Rabaglio-Poretti M, Gelber RD, Coates AS, Di Leo A, Regan MM, Goldhirsch A; SOLE Investigators.

Lancet Oncol. 2018 Jan;19(1):127-138. doi: 10.1016/S1470-2045(17)30715-5. Epub 2017 Nov 17.

PMID:
29158011
5.

Weekly cabazitaxel plus prednisone is effective and less toxic for 'unfit' metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial.

Climent MÁ, Pérez-Valderrama B, Mellado B, Fernández Parra EM, Fernández Calvo O, Ochoa de Olza M, Muinelo Romay L, Anido U, Domenech M, Hernando Polo S, Arranz Arija JÁ, Caballero C, Juan Fita MJ, Castellano D.

Eur J Cancer. 2017 Dec;87:30-37. doi: 10.1016/j.ejca.2017.09.028. Epub 2017 Nov 2.

PMID:
29102858
6.

Performance of Sustainable Fly Ash and Slag Cement Mortars Exposed to Simulated and Real In Situ Mediterranean Conditions along 90 Warm Season Days.

Ortega JM, Esteban MD, Sánchez I, Climent MÁ.

Materials (Basel). 2017 Oct 31;10(11). pii: E1254. doi: 10.3390/ma10111254.

7.

Impedance Spectroscopy Study of the Effect of Environmental Conditions on the Microstructure Development of Sustainable Fly Ash Cement Mortars.

Ortega JM, Sánchez I, Climent MÁ.

Materials (Basel). 2017 Sep 25;10(10). pii: E1130. doi: 10.3390/ma10101130.

8.

Short-Term Behavior of Slag Concretes Exposed to a Real In Situ Mediterranean Climate Environment.

Ortega JM, Sánchez I, Cabeza M, Climent MÁ.

Materials (Basel). 2017 Aug 8;10(8). pii: E915. doi: 10.3390/ma10080915.

9.

Long-Term Behaviour of Fly Ash and Slag Cement Grouts for Micropiles Exposed to a Sulphate Aggressive Medium.

Ortega JM, Esteban MD, Rodríguez RR, Pastor JL, Ibanco FJ, Sánchez I, Climent MÁ.

Materials (Basel). 2017 May 30;10(6). pii: E598. doi: 10.3390/ma10060598.

10.

Influence of Silica Fume Addition in the Long-Term Performance of Sustainable Cement Grouts for Micropiles Exposed to a Sulphate Aggressive Medium.

Ortega JM, Esteban MD, Rodríguez RR, Pastor JL, Ibanco FJ, Sánchez I, Climent MÁ.

Materials (Basel). 2017 Aug 2;10(8). pii: E890. doi: 10.3390/ma10080890.

11.

A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCuLating Endothelial cellS) Study (SOGUG-CEC-2011-01).

García-Donas J, Leon LA, Esteban E, Vidal-Mendez MJ, Arranz JA, Garcia Del Muro X, Basterretxea L, González Del Alba A, Climent MA, Virizuela JA, Álvarez C, Sepúlveda J, Anido U, López C, Ortiz-Morales MJ, Pérez X, Rodriguez-Antona C, Rodriguez-Moreno JF, Hernando S, Castellano D.

Eur Urol Focus. 2017 Oct;3(4-5):430-436. doi: 10.1016/j.euf.2016.09.004. Epub 2016 Oct 4.

PMID:
28753791
12.

Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies.

Castellano D, Maroto JP, Espinosa E, Grande E, Bolós MV, Llinares J, Esteban E, González Del Alba A, Climent MA, Arranz JA, Méndez MJ, Fernández Parra E, Antón-Aparicio L, Bayona C, Gallegos I, Gallardo E, Samaniego L, García Donas J.

Expert Opin Drug Saf. 2018 Jun;17(6):573-579. doi: 10.1080/14740338.2017.1330410. Epub 2017 Aug 28.

PMID:
28535693
13.

Aged patients with metastatic castration resistant prostate cancer: Should we treat with chemotherapy?

Climent MÁ, Torregrosa MD, Vázquez S, Gironés R, Arranz JA.

Cancer Treat Rev. 2017 Apr;55:173-180. doi: 10.1016/j.ctrv.2017.03.007. Epub 2017 Apr 3. Review.

PMID:
28411479
14.

Deep sequencing reveals microRNAs predictive of antiangiogenic drug response.

García-Donas J, Beuselinck B, Inglada-Pérez L, Graña O, Schöffski P, Wozniak A, Bechter O, Apellániz-Ruiz M, Leandro-García LJ, Esteban E, Castellano DE, González Del Alba A, Climent MA, Hernando S, Arranz JA, Morente M, Pisano DG, Robledo M, Rodriguez-Antona C.

JCI Insight. 2016 Jul 7;1(10):e86051. doi: 10.1172/jci.insight.86051.

15.

SNPs associated with activity and toxicity of cabazitaxel in patients with advanced urothelial cell carcinoma.

Duran I, Hagen C, Arranz JÁ, Apellaniz-Ruiz M, Pérez-Valderrama B, Sala N, Lainez N, García-Del Muro X, Noguerón E, Climent MÁ, Maroto P, Font A, García-Donas J, Gallardo E, López-Criado P, González Del Alba A, Sáez MI, Vázquez S, Luque R, Rodríguez-Antona C.

Pharmacogenomics. 2016 Apr;17(5):463-71. doi: 10.2217/pgs.15.186. Epub 2016 Mar 29.

PMID:
27020167
16.

Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.

Bellet M, Gray KP, Francis PA, Láng I, Ciruelos E, Lluch A, Climent MA, Catalán G, Avella A, Bohn U, González-Martin A, Ferrer R, Catalán R, Azaro A, Rajasekaran A, Morales J, Vázquez J, Fleming GF, Price KN, Regan MM.

J Clin Oncol. 2016 May 10;34(14):1584-93. doi: 10.1200/JCO.2015.61.2259. Epub 2016 Jan 4.

17.

Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancer.

Maroto P, Solsona E, Gallardo E, Mellado B, Morote J, Arranz JÁ, Gómez-Veiga F, Unda M, Climent MÁ, Alcaraz A.

Crit Rev Oncol Hematol. 2016 Apr;100:127-36. doi: 10.1016/j.critrevonc.2015.07.011. Epub 2015 Aug 1. Review.

PMID:
26363809
18.

Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer.

Climent MÁ, León-Mateos L, González Del Alba A, Pérez-Valderrama B, Méndez-Vidal MJ, Mellado B, Arranz JÁ, Sánchez-Hernández A, Cassinello J, Olmos D, Carles J.

Crit Rev Oncol Hematol. 2015 Nov;96(2):308-18. doi: 10.1016/j.critrevonc.2015.05.019. Epub 2015 Jun 8. Review.

PMID:
26100652
19.

Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature.

Guillem V, Climent MA, Cassinello J, Esteban E, Castellano D, González-Larriba JL, Maroto P, Camps C.

BMC Urol. 2015 Mar 13;15:15. doi: 10.1186/s12894-015-0008-7. Review.

20.

Efficacy and safety of neoadjuvant chemotherapy with concurrent liposomal-encapsulated doxorubicin, paclitaxel and trastuzumab for human epidermal growth factor receptor 2-positive breast cancer in clinical practice.

Gavilá J, Guerrero Á, Climent MÁ, Fernández A, Gozalbo F, Carrascosa M, Camps J, Guillem V, Ruiz A.

Int J Clin Oncol. 2015 Jun;20(3):480-9. doi: 10.1007/s10147-014-0727-x. Epub 2014 Jul 11.

PMID:
25011497

Supplemental Content

Loading ...
Support Center